Exelixis

Exelixis
Name	Exelixis, Inc.
Type	Public
Industry	Biotechnology
Founded	1994
Founder	G. Steven Burrill, Alexis Borisy, Gerald F. Joyce
Headquarters	Alameda, California, United States
Key people	Michael M. Morrissey, Roy A. Baynes, Kevin R. Johnson
Products	Cabozantinib (Cabometyx, Cometriq), other oncology agents

Exelixis

Exelixis is a biotechnology company focused on oncology drug discovery and development. Founded in 1994 in California, it has concentrated on small molecule therapeutics, translational research, and strategic collaborations with pharmaceutical firms and academic institutions. The company is best known for developing cabozantinib and advancing kinase inhibitor programs through regulatory approvals and commercialization efforts.

History

Exelixis was established in 1994 amid the 1990s biotechnology boom with early backing from investors such as G. Steven Burrill, Alexis Borisy, and founders including Gerald F. Joyce. In the 1990s and 2000s Exelixis engaged with entities like Amgen, Genentech, GlaxoSmithKline, Merck & Co., and Bristol-Myers Squibb through research collaborations and licensing agreements. The company navigated the dot-com and biotech market cycles alongside peers such as Genentech, Amgen, Biogen, Gilead Sciences, and Celgene. Regulatory milestones involved agencies including the U.S. Food and Drug Administration and the European Medicines Agency as Exelixis pursued approvals for oncology indications. Leadership changes over time connected the company to executives who had worked at organizations like AbbVie, Pfizer, Eli Lilly and Company, and Bayer.

Business model and operations

Exelixis operates a hybrid model combining in-house drug discovery, clinical development, and partnerships with major pharmaceutical companies such as Ipsen and Takeda Pharmaceutical Company. The company’s operations span research facilities in Alameda and commercial coordination with distributors and specialty pharmacies including networks used by McKesson Corporation and Cardinal Health. Exelixis leverages collaborations with academic centers like Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center for investigator-initiated trials. Commercial strategies align with payers and health technology assessment bodies including Centers for Medicare & Medicaid Services and national agencies in markets such as United Kingdom and Japan.

Research and development

Exelixis’s R&D historically emphasized small molecule kinase inhibitors and target validation grounded in preclinical models associated with laboratories at Stanford University, Harvard Medical School, University of California, San Francisco, and Broad Institute. The company applied medicinal chemistry approaches influenced by work at Scripps Research Institute and utilized translational science infrastructure comparable to programs at National Institutes of Health and National Cancer Institute. Clinical development programs interacted with cooperative groups and trial networks including Eastern Cooperative Oncology Group and Alliance for Clinical Trials in Oncology. Regulatory interactions implicated advisory committees such as panels convened by the U.S. Food and Drug Administration.

Products and pipeline

Exelixis’s flagship approved agent is cabozantinib, marketed in collaboration with partners under brand names in indications including advanced renal cell carcinoma and hepatocellular carcinoma; these approvals involved regulatory bodies like the U.S. Food and Drug Administration and European Medicines Agency. The company’s pipeline has included agents targeting receptor tyrosine kinases with programs that underwent clinical assessment alongside comparator agents developed by companies such as Roche, Novartis, AstraZeneca, Merck Sharp & Dohme, and Bristol-Myers Squibb. Exelixis pursued combination studies with immune checkpoint inhibitors developed by Merck & Co. (pembrolizumab) and Bristol-Myers Squibb (nivolumab, ipilimumab) and studied biomarkers alongside platforms at Foundation Medicine and Guardant Health. Earlier discovery-stage projects referenced scientific advances from institutions like Cold Spring Harbor Laboratory and University of California, San Diego.

Collaborations and partnerships

Exelixis established commercialization and licensing collaborations with companies including Ipsen for international rights and Takeda Pharmaceutical Company for regional arrangements. Strategic alliances have included research collaborations with biotech and pharma firms such as Amgen, Genentech, GlaxoSmithKline, Bristol-Myers Squibb, and academic partnerships with Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Financial and investor relationships connected Exelixis to venture capital and public markets involving Goldman Sachs, Morgan Stanley, J.P. Morgan Chase, and institutional investors like Vanguard Group and BlackRock. Clinical trial sites and cooperative research were coordinated with networks such as SWOG Cancer Research Network and Eastern Cooperative Oncology Group.

Corporate governance and financials

Corporate governance at Exelixis has involved a board with members experienced at companies like Pfizer, Eli Lilly and Company, Amgen, Gilead Sciences, and Biogen and advisory interactions with regulatory agencies such as the U.S. Securities and Exchange Commission. Financial performance, reporting, and capital raising have engaged investment banks including Goldman Sachs, Citigroup, Barclays, and audit relationships with firms comparable to the largest accounting networks. Public filings and shareholder communications align with practices observed among Nasdaq-listed biotechnology peers including Regeneron Pharmaceuticals and Vertex Pharmaceuticals. Executive leadership transitions referenced careers involving companies such as AbbVie, Bayer, Takeda, and Novartis.

Category:Biotechnology companies